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Background: Global Public Health Burden of Heart Failure reported the growing prevalence of heart failure which 
is 64.3 million affected in 2020 worldwide with half of the case classified as Heart Failure Preserved Ejection 
Fraction (HFpEF). It is well known that someone who has been diagnosed with heart failure will have a poorer 
quality of life/QoL. β-blocker is a heart rate lowering agent with a potency to improve the patient’s clinical 
outcomes, one of them is QoL.
Objective: This study aimed to observe and evaluate the effect of bisoprolol, a type of β-blocker, in the improve-
ment of HFpEF patient’s QoL. 
Method: This study is a retrospective cohort following HFpEF patients who received bisoprolol and HFpEF 
patients who did not receive bisoprolol. The study participants were selected using purposive sampling method. 
Result: Our study found that from all HFpEF patients who received bisoprolol 102 patients had a good QoL and 
2 patients had a poor QoL (p=0.000) according to Minnesota Living With Heart Failure Questionnaire (MLHFQ). 
The median physical score in the patient who did not receive bisoprolol was 10 while the median score of the 
patient who received β-blocker was 4 (p=0.000). The mean emotional score for the patients who did not receive 
β-blocker was 3 while the mean score of the patients who received β-blocker was 1 (p=0.000). 
Conclusion: We conclude that the use of bisoprolol could improve the HFpEF patient’s QoL evaluated by total 





 Global Public Health Burden of Heart Failure reported that 
there was an increasing prevalence of heart failure from 26 million 
people affected in 2017 to 64.3 million people worldwide in 2020 with 
half of the case classified as heart failure preserved ejection fraction/H-
FpEF1. Heart failure preserved ejection fraction or shortened as HFpEF 
is one of heart failure classification in which the ejection fraction is 
>50% based on European Society of Cardiology/ESC 2016 guideline 
for diagnosis and treatment of acute and chronic heart failure2. 
Patients with HFpEF are older and highly symptomatic with a poor 
QoL3. Because of that condition, the challenge to achieve our goals in 
treating HF patients must be face it, which are to improve their clinical 
status, functional capacity, and quality of life, prevent hospital admis-
sion and reduce mortality.2
 Beta blocker/β-blocker is a heart rate lowering agent that 
may increase the clinical outcome of heart failure patients.4 ESC 2016 
guideline for diagnosis and treatment of acute and chronic heart failure 
stated the usage of β-blocker as a first-line recommendation therapy 
combined with ACE inhibitor.2 One of the most important outcomes 
that should be evaluated and become the main goal of therapy as we
know above is the patient’s quality of life/QoL2 The Cardiac Insufficien-
cy Bisoprolol Study in Elderly/CIBIS-ELD stated an increase in the 
quality of life from uptitration of β-blocker in patients with heart 
failure.5 Besides showing the effect of β-blocker uptitration on the 
quality of life, the study also evaluates the effect of β-blocker uptitra-
tion on the clinical variable such as heart rate where they found a 
reduction in the heart rate at the end of the study.5 Based on this fact, 
we think that there should be a study to observe and evaluate the effect 
of β-blocker such as bisoprolol on the quality of life of HFpEF patients.
2. Methods
 Our study was a retrospective cohort performed in Saiful 
Anwar Hospital, Malang from April to July 2021. HFpEF patients data 
who were treated with bisoprolol and HFpEF patients who did not 
receive bisoprolol were collected according to the medical record. We 
used purposive sampling method with inclusion criteria consisted of: 
(1) age 30-75 years old diagnosed with heart failure based on the 
definition stated in the 2016 ESC guideline; (2) echocardiography 
criteria of LV EF ≥50%; (3) H2FPEF score confirmed as an HFpEF; (4) 
confirmed as a patient in Saiful Anwar Hospital; (5) signed informed 
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consent to participate in the research. The exclusion criteria were (1) 
patient died before the study interview (2) patient was waiting for the 
procedure such as cardiac surgery, pacemaker implantation, CABG or 
heart transplant (3) patient was in a state of severe emotional stress 
based on a psychiatric diagnosis from medical record data; (4) patient 
with chronic diseases such as chronic kidney disease or pulmonary 
hypertension 
 The categorical variables were analyzed using Chi-square 
and all continuous variables were analyzed by T-test for data with 
normal distribution or Mann-Whitney for data not normally distribut-
ed. The confidence interval used in this study is 95% (α=0.05).
3. Results
 Our study followed 217 patients with 22 patients categorized 
as poor QoL and 195 patients categorized as good QoL (Table 1). Based 
on the data analysis, there were statistically significant differences in 
the QoL on some characteristics including HT (p=0.004), heart rate 
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Table 1. Sample Characteristics
(p=0.000), and SBP (p=0.000). Other sample characteristics such as 
gender (p=0.510), age (0.029), DM (0.365), ischemic (p=0.121),   
smoker (p=0.221), height (p=0.135), weight (p=0.071), BMI 
(0.502), NYHA (p=0.401), EF (p=0.721), LAVI (p=0.151), TAPSE 
(0.486), E/A (0.573) and PCWP (0.365) did not show a significant 
difference.
 Table 2 summarized the difference in the QoL between the 
patient who received bisoprolol and the patient who did not receive 
β-blocker. We found that 102 patients who received bisoprolol had a 
good QoL meanwhile 2 other patients who also received bisoprolol had 
a poor QoL. In the group that did not receive bisoprolol, 93 patients had 
a good QoL and 20 patients had poor QoL. The mean comparison of 
bisoprolol (2 categories) showed a p-value of 0.000 (p<0,005) which 
meant a statistically significant difference of the β-blocker usage in the 
quality of life. We also found the odds ratio/OR=10.97 which meant 
that the patients who received bisoprolol had a higher odds of 10.97 
times to have a good QoL (CI 95%: 2.49-48.2).      
 Poor QoL (n=22) Good QoL 
(n=195) 
p value 
F % F % 
GenderF L 13 6 100 46.1 0.510 
P 9 4.1 95 43.8 
Aget Mean±SD 63.41±9.34 57.73±12.18 0.029 
HTF No 2 9 77 35.5 0.004 
Yes 20 9.2 118 54.4 
DMF No 17 7.8 165 76.0 0.365 
Yes 5 2.3 30 13.8 
IschemicF No 7 3.2 97 44.7 0.121 
Yes 15 6.9 98 45.2 
SmokingF No 16 7.4 165 76.0 0.221 
Yes 6 2.8 30 13.8 
HeightM (Median) 163 160 0.135 
WeightM (Median) 69 63 0.071 
BMIt Mean±SD 25.4±3.39 24.88±3.36 0.502 
BMIC Underweight 0 0 3 0.9 0.829 
Normal 5 2.3 54 21.2 
overweight 6 2.8 52 17.1 
Obesity 1 10 4.6 69 21.7 
Obesity 2 1 0.5 17 7.4 
Heart Ratet Mean±SD 79.09±6.15 73.27±7.18 0.000 
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 Based on Table 3, the median physical score from patients 
who did not receive bisoprolol was ten meanwhile the median score 
from patients who received bisoprolol was four. Statistical analysis with 
Mann-Whitney showed a significance of 0.000 (p<0.05). This showed 
that the mean physical score of patients who did not receive bisoprolol 
and patients who received bisoprolol differed significantly. Our study 
also found the median emotional score of patients who did not receive 
bisoprolol was three. In the meantime, the median emotional score 
from patients who received bisoprolol was one. Statistical analysis with 
Mann-Whitney showed a p-value of 0.000 (p<0.05) which meant there 
was a significant difference in mean emotional score in the patient who 
did not receive bisoprolol and patients who received bisoprolol, with a 
lower score in the patient who received bisoprolol according to 
MLHFQ.
4. Discussion
 HFpEF is a heterogeneous syndrome accompanied by a 
variety of risk factors that contribute to the development of the 
condition which includes hypertension, obesity, diabetes mellitus,
coronary heart disease, valvular heart disease, atrial fibrillation, 
obstructive pulmonary disease, chronic kidney disease, and anemia.6,7
 We found that hypertension had a significant influence on 
the QoL in both groups, patients treated with bisoprolol and not treated 
with bisoprolol (p=0.004). HFpEF patients without any history of 
hypertension in our study mostly exhibited a good QoL. Literature 
shows a negative correlation between hypertension and QoL, when the 
patient has a history of hypertension or severe hypertension, the QoL 
will be lower.8 Our study did not act in accordance with this negative 
correlation because in our study 118 patients with hypertension had a 
good QoL meanwhile only 20 patients with hypertension had a poor 
QoL. This might be influenced by a good blood pressure control done 
by the patient, as mentioned in Lee et al study in which the improve-
ment of quality of life could have an effect on blood pressure control.8
  Heart rate evaluation is among the most studied variable 
because of its relation with the clinical outcome of a patient with 
cardiovascular disease, as the study from O’Neal et al who concluded
Table 2.  Mean Comparison of β-blocker to Total Score
SBPM (Median) 132 (110-160) 122 (100-165) 0.000 
DBPM (Median) 80 (65-110) 80 (51-115) 0.078 
NYHAC 1 14 6.5 125 57.6 0.401 
2 7 3.2 68 31.3 
3 1 0.5 2 0.9 
Total H2FPEFC 2 9 4.12% 65 29.81% 0.774 
3 8 3.66% 72 22.02% 
4 2 0.91% 45 20.64% 
5 1 0,45 9 4.12% 
6 2 0.91% 4 1.83% 
LAVIM (Median) 24.5 27.95  0.151 
TAPSEt Mean±SD 2.065±0.32 2.006±0.388 0.486 
E/AM (Median) 0.8 0.9 0.573 
PCWPM (Median) 16.05 (15-47) 16.0 (11-36) 0.365 
Note: F  = Fisher exact test; C = Chi square test; t = T test; M = Mann Whitney Test 
QoL= Quality of Life; HT = Hypertension; DM = Diabetes Mellitus; BMI = Body Mass Index; SBP = Systolic Blood Pressure; DBP = Diastolic Blood 
Pressure; NYHA = New York Heart Association; LAVI= Left Atrial Volume Index; TAPSE = Tricuspid Annular Plane Systolic Excursion; PCWP = 
Pulmonary Capillary Wedge Pressure 
 
 Poor QoL (n=22) Good QoL (n=195) p-value 
(OR) 
CI 95% 
f % F % 
Bisoprolol No 20 9.2 93 42.9 0.000 
(10.97) 
2.49-48.2 
Yes 2 0.9 102 47.6 
Note: 
QoL = Quality of Life; CI = Confidence Interval; OR = Odds Ratio 
A.A.D. Adityawati et al. Heart Sci J 2021; 2(4): 25-30
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can lead to the disruption of baroreceptor reflex17 and the over 
secretion of catecholamines18. Catecholamine (including dopamine, 
epinephrine, and norepinephrine) is an important stress response of the 
body that could be activated by an emotional response such as anxiety 
or fear11. This discovery leads to a more holistic approach to HFpEF 
management in the hope to suppress the secretion of catecholamines. 
Prolonged catecholamine exposure could worsen the physical and 
psychological outcome of the patient that could result in a change of 
mood and a worse QoL in the patient with HFpEF.19
 β-blocker can also act as an anti-remodeling in the HFpEF 
patient. Structurally, there is a difference in the remodeling process of 
HFpEF and other heart failures.20 In HFpEF, the heart underwent 
concentric hypertrophy of the left ventricle even though some of the 
patients still have a normal left ventricle geometry.21 The use of 
β-blocker in the past study showed its role as a cardiac antiremodelling 
although the underlying mechanism was still unclear. The suggested 
mechanism was a reduction of left ventricle sphericity and functional 
regurgitation of the mitral.22 We should all keep in mind that almost all 
past studies of the heart failure patient had given the patient ACE-in-
hibitor before the administration of β-blocker which meant that the 
anti-remodeling effect was significantly influenced by the use of 
ACE-inhibitor and we could not estimate the same result if we eliminate 
the use of ACE-inhibitor.23
5. Conclusion
 Bisoprolol could improve the quality of life (total score, 
physical score, and emotional score) of HFpEF patients compared to a 
patient who did not receive bisoprolol.
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that greater count of heart rate at rest is a factor that influences the 
clinical outcome in the HFpEF patient.9 Our study found that patients 
who had fewer heartbeats per minute mostly had a good QoL while 
patients with greater heartbeats per minute had a poor QoL. An 
increase in heart rate by 5-10 beats per minute will increase the mortal-
ity risk in the general mortality or mortality related to cardiovascular 
and also in the risk of hospitalization in the heart failure patient such as 
HFpEF patient, which is this finding had a great effect on the patient’s 
QoL.10 An increase in the heart rate, reflects the increase in energy cost, 
activation of the sympathetic system, and excretion of catecholamines 
in heart failure patients. The upsurge of catecholamines in HFpEF 
patients might be accountable for a poorer outcome in patients with 
HFpEF both physically and psychologically.11 There are some 
neurotransmitters that have an effect on someone’s mood that will also 
affect the QoL at the end.11 An increase in the heart rate facilitated by 
activation of the sympathetic system can also affect the blood pressure 
and initiate an upsurge in catecholamines as compensation. This can 
lead to a change in the patient’s physical and psychological state.
 Evaluation of the QoL by MLHFQ categorized 102 patients 
who received bisoprolol into a good QoL (47,0%). From the Fisher 
exact test, we found p=0.000 (p<0.05) which meant there was a 
significant difference in the QoL between the patient who received 
bisoprolol and the patient who did not receive bisoprolol. In our study, 
the patient who did not receive bisoprolol mostly had a poor QoL. This 
finding was supported by CIBIS ELD who found that the dose up-titra-
tion of β-blocker could improve the HFpEF patient’s QoL evaluated by 
the SF-36 questionnaire.5,12 Kojima also had a similar discovery, he 
found that the use of β-blocker affects the QoL in a span of one year.13 
We hope that the improvement of HFpEF patient’s QoL when treated by 
β-blocker, like we found in our study, could give a new insight into the 
management of HFpEF even though there was still a big dispute.14
   In the progression of heart failure, there is a hyperactivation 
of the sympathetic system, which manifest as an increase in the heart 
rate and an increase in the stimulation of β-adrenergic receptor at 
cardiomyocytes result an activation of Beta1AR-stimulating G (Gs) 
protein–adenylate cyclase–cyclic adenosine monophosphate 
(cAMP)–protein kinase A (PKA).15 In the chronic condition, this can 
lead to persistent stimulation of β1-adrenergic receptor which result in 
cardiomyocytes apoptosis, hypertrophy, and also fibrosis of the heart. 
Β-blocker has a therapeutic role in the pathophysiology of HFpEF 
where it can lower the sympathetic system activation and hope to 
inhibit the persistent stimulation of β1-adrenergic receptor 15 and 
inhibit the delay of left ventricle relaxation as the result of the heart’s 
inflexibility that can lead to an increase in diastolic filling pressure of 
the ventricle and reduction of the cardiac output.16 
 Another beneficial effect of beta blocker is the direct protec-
tion of myocardial from catecholamine toxicity. When HFpEF patients 
experience a reduction of cardiac output, the body will try to compen-
sate for it by doing a counter-regulation. One mechanism is by increas-
ing the regulation effect of the sympathetic system, unfortunately, this
  Without Bisoprolol (n=113) Bisoprolol (n=113) p-value 
Median Min-max Mean±SD Median Min-max Mean±SD 
Physical score 10 (0-53) 13.84±11.01 4 (0-24) 5.94±4.95 0.000 
Emotional 
score 
3 (0-36) 6.02±6.61 1 (0-12) 1.83±2.16 0.000 
Note: 
SD = Standard Deviation 
Table 3. Mean Comparison of β-blocker to Physical Score and Emotional Score
A.A.D. Adityawati et al. Heart Sci J 2021; 2(4): 25-30
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